Stock Watch: Bridgebio’s Endpoint A Bridge Too Far
Switch From Surrogate To Clinical Endpoint Between Phase II and III Had Big Risks
The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.
You may also be interested in...
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.
After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.